Stock LCTX LINEAGE CELL THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Lineage Cell Therapeutics, Inc.

Equities

LCTX

US53566P1093

Delayed Nyse
Other stock markets
 03:55:20 2024-06-10 pm EDT 		5-day change 1st Jan Change
0.9333 USD -3.78% Intraday chart for Lineage Cell Therapeutics, Inc. -8.42% -14.30%
May. 21 Lineage Cell Therapeutics, Inc. Announces Updates to 2nd Annual Spinal Cord Injury Investor Symposium CI
May. 09 Transcript : Lineage Cell Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024

Evolution of the average Target Price on Lineage Cell Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

239d8e6a5a81ff09a3616e7ece6207.ncy78REluAZAQS9GSaIa4ie5pQVet2qebmDxdNcsprg.0_2Kv11A9Hx0dXYIJc5itXPw4kdq0Tr6HzO1Q5lclOzL-syJV276UzQGGw~f6e82d3ea2d80fa540e593b704e2253a

Analyst Recommendations on Lineage Cell Therapeutics, Inc.

Baird Starts Lineage Cell Therapeutics at Outperform With $5 Price Target MT
B. Riley Initiates Lineage Cell Therapeutics at Buy with $4 Price Target, Says Platform, Pipeline Currently Undervalued MT
LINEAGE CELL THERAPEUTICS : Noble Capital Initiates Coverage on Lineage Cell Therapeutics With Outperform Rating, $8 Price Target MT
LINEAGE CELL THERAPEUTICS : Chardan Suspends Coverage on Lineage Cell Therapeutics at Buy Rating With $4 Price Target MT
LINEAGE CELL THERAPEUTICS : Cantor Fitzgerald Starts Lineage Cell Therapeutics at Overweight With $6 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
0.97 USD
Average target price
5.2 USD
Spread / Average Target
+436.08%
High Price Target
7 USD
Spread / Highest target
+621.65%
Low Price Target
4 USD
Spread / Lowest Target
+312.37%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Lineage Cell Therapeutics, Inc.

Baird
B. Riley
Noble Capital
Chardan
Cantor Fitzgerald

Ratings for Lineage Cell Therapeutics, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. LCTX Stock
  4. Consensus Lineage Cell Therapeutics, Inc.